Key Highlights

  • Net loss per share was USD 0.79 against an estimate of USD 0.02 in earnings.
  • Product sales, net, were USD 35.93 million against an estimate of USD 37.28 million.
  • Income from operations was USD 4.50 million, compared with a USD 26.39 million loss.
  • Net loss was USD 57.36 million, compared with USD 30.92 million.

Omeros (NASDAQ:OMER) reported net product sales of USD 35.93 million for the third quarter of 2026, with no product sales in the prior-year quarter, against an estimate of USD 37.28 million. Basic and diluted net loss per share was USD 0.79, compared with USD 0.47, against an estimate of USD 0.02 in earnings.

Net loss was USD 57.36 million, compared with USD 30.92 million. The company recorded a net loss from continuing operations of USD 63.83 million and Net Income from discontinued operations of USD 6.47 million.

Third Quarter Results

Cost of product sales was USD 826 thousand. Research and Development expenses were USD 16.06 million, compared with USD 16.00 million, and selling, general and administrative expenses were USD 14.55 million, compared with USD 10.40 million. Total costs and expenses were USD 31.43 million, compared with USD 26.39 million.

Income from operations was USD 4.50 million, compared with a loss from operations of USD 26.39 million. Interest and other income was USD 1.87 million, compared with USD 616 thousand, and interest expense, net of remeasurement adjustments and other, was USD 6.22 million, compared with a gain of USD 13.36 million.

Financial Instruments and Net Result

The company recorded a net loss of USD 62.02 million on the change in Fair Value of financial instruments, compared with a loss of USD 8.82 million, and a loss of USD 1.91 million on early extinguishment of its 2029 Notes. The loss from continuing operations before income tax was USD 63.78 million, compared with USD 21.24 million, and income tax expense was USD 46 thousand.

Net loss per share from continuing operations was USD 0.88, compared with USD 0.32, and net income per share from discontinued operations was USD 0.09, compared with a loss of USD 0.15. For the nine months, product sales, net, were USD 74.36 million, and net income was USD 11.94 million, compared with a net loss of USD 89.80 million. Basic Earnings per share for the nine months were USD 0.16 and Diluted Earnings per Share were USD 0.13, compared with a loss of USD 1.47.

Balance Sheet

Cash and cash equivalents were USD 5.07 million at September 30, 2026, compared with USD 9.66 million at December 31, 2025, and short-term investments were USD 90.18 million, compared with USD 162.14 million. The OMIDRIA contract Royalty asset was USD 25.73 million in current Assets and USD 87.90 million in non-current assets. Receivables were USD 23.10 million.

Total current assets were USD 150.89 million, compared with USD 215.67 million, and total assets were USD 248.10 million, compared with USD 325.63 million. The company reported a total shareholders' Deficit of USD 89.97 million, compared with USD 121.23 million, and an accumulated deficit of USD 901.76 million.

Omeros Q3 2026 Earnings: Key Takeaways

Omeros reported third quarter 2026 net product sales of USD 35.93 million, income from operations of USD 4.50 million and a net loss of USD 57.36 million. Short-term investments were USD 90.18 million at September 30, 2026.